MX379126B - Formulación de factor viii. - Google Patents

Formulación de factor viii.

Info

Publication number
MX379126B
MX379126B MX2017000862A MX2017000862A MX379126B MX 379126 B MX379126 B MX 379126B MX 2017000862 A MX2017000862 A MX 2017000862A MX 2017000862 A MX2017000862 A MX 2017000862A MX 379126 B MX379126 B MX 379126B
Authority
MX
Mexico
Prior art keywords
factor viii
viii formulation
formulation
relates
factor
Prior art date
Application number
MX2017000862A
Other languages
English (en)
Other versions
MX2017000862A (es
Inventor
Christina Bodenbender
Hubert Metzner
Uwe Liebing
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Ltd filed Critical Csl Ltd
Publication of MX2017000862A publication Critical patent/MX2017000862A/es
Publication of MX379126B publication Critical patent/MX379126B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a composiciones de Factor VIII y su uso.
MX2017000862A 2014-08-04 2015-07-24 Formulación de factor viii. MX379126B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14179732 2014-08-04
PCT/EP2015/066999 WO2016020210A1 (en) 2014-08-04 2015-07-24 Csl behring gmbh

Publications (2)

Publication Number Publication Date
MX2017000862A MX2017000862A (es) 2017-05-01
MX379126B true MX379126B (es) 2025-03-10

Family

ID=51298563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000862A MX379126B (es) 2014-08-04 2015-07-24 Formulación de factor viii.

Country Status (16)

Country Link
US (1) US10238718B2 (es)
EP (1) EP3177317B1 (es)
JP (1) JP6516829B2 (es)
KR (1) KR102192494B1 (es)
CN (1) CN106687126B (es)
AU (1) AU2015299224B2 (es)
BR (1) BR112017002090B1 (es)
DK (1) DK3177317T3 (es)
ES (1) ES2788870T3 (es)
IL (1) IL250343B (es)
MX (1) MX379126B (es)
NZ (1) NZ729629A (es)
PL (1) PL3177317T3 (es)
RU (1) RU2689338C2 (es)
SG (2) SG10201900598TA (es)
WO (1) WO2016020210A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
JP7113429B2 (ja) 2016-11-29 2022-08-05 Ｓｐｉｂｅｒ株式会社 タンパク質組成物、その製造方法及び熱安定性向上方法
WO2018132874A1 (en) * 2017-01-19 2018-07-26 Csl Limited Method of preventing an immune response with alpha- 1 anti-trypsin
CN111655230A (zh) 2017-11-07 2020-09-11 拉尼医疗有限公司 使用可吞服药物递送装置递送到肠道组织中的凝血因子制剂
CN113105562B (zh) * 2018-09-26 2023-12-01 安源医药科技（上海）有限公司 突变型单链人凝血因子viii在制备融合蛋白中的应用
CN112138149A (zh) * 2019-06-28 2020-12-29 北京基科晟斯医药科技有限公司 重组凝血因子viii制剂
US20220380439A1 (en) 2020-11-09 2022-12-01 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
DE69029765T2 (de) 1989-07-24 1997-05-15 Bayer Ag Stabilisierung von hochgereinigten Proteinen
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
DE69333928T2 (de) 1992-04-30 2006-08-17 Probitas Pharma Inc., Los Angeles Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes
CZ290342B6 (cs) * 1992-10-02 2002-07-17 Genetics Institute Inc. Kompozice stabilní při skladování, obsahující koagulační faktor VIII a neiontovou povrchově aktivní látku a způsob její výroby
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
SE9501189D0 (sv) 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
PT2193809E (pt) * 1999-02-22 2015-08-24 Baxter Int Formulações de fator viii livres de albumina
EP2305312B1 (en) 2001-10-10 2015-03-04 ratiopharm GmbH Remodelling and glycoconjugation of follicle-stimulating hormone (FSH)
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
ES2676644T3 (es) 2003-12-19 2018-07-23 Novo Nordisk Health Care Ag Composiciones estabilizadas de polipéptidos de factor VII
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
US7523304B2 (en) * 2005-11-22 2009-04-21 Ntt Docomo, Inc. Generation of set coverings with free riders, and generation of ordered sets of meeting points, in systems which include, but are not limited to, systems for broadcast encryption and systems for certificate revocation
AU2007212021B2 (en) 2006-02-07 2013-06-06 Takeda Pharmaceutical Company Limited Stabilized compositions of proteins having a free thiol moiety
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
EP2010222A1 (en) 2006-03-31 2009-01-07 Baxter International Inc. Pegylated factor viii
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US8754194B2 (en) 2006-12-22 2014-06-17 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
US8133865B2 (en) 2006-12-27 2012-03-13 Nektar Therapeutics von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
ES2364118T3 (es) 2007-07-11 2011-08-25 Novo Nordisk A/S Purificación de factor viii usando una resina de modo mixto o multimodal.
AU2008323768A1 (en) 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
CN103497247A (zh) 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 缀合的因子viii分子
ATE551050T1 (de) * 2008-09-03 2012-04-15 Octapharma Ag Stabilisierte zusammensetzungen für rekombinant hergestellten faktor viii
PT2349342T (pt) 2008-10-17 2018-10-26 Baxalta Inc Factores sanguíneos modificados que compreendem um baixo grau de polímero solúvel na água
BRPI0921429B1 (pt) 2008-11-07 2022-07-12 Takeda Pharmaceutical Company Limited Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
JP2012518029A (ja) 2009-02-19 2012-08-09 ノヴォ・ノルディスク・アー／エス 第ｖｉｉｉ因子の修飾
JP5770161B2 (ja) 2009-04-06 2015-08-26 ノヴォ ノルディスク アー／エス 血小板への第ｖｉｉｉ因子タンパク質の標的送達
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
WO2011101242A1 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
EP2536754A1 (en) 2010-02-16 2012-12-26 Novo Nordisk A/S Factor viii fusion protein
JP5826772B2 (ja) 2010-02-16 2015-12-02 ノヴォ ノルディスク アー／エス コンジュゲートタンパク質
EP2560686A2 (en) 2010-04-21 2013-02-27 Novo Nordisk A/S Selective modification of proteins
US20130183280A1 (en) 2010-07-15 2013-07-18 Novo Nordisk A/S Stabilized factor viii variants
US8795658B2 (en) 2010-09-17 2014-08-05 Baxter International Inc. Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH
AU2012318292B2 (en) * 2011-10-18 2015-08-20 Csl Limited Method for improving the stability of purified Factor VIII after reconstitution
CN102580062B (zh) * 2012-03-09 2017-03-08 中国医学科学院输血研究所 人凝血因子VIII与vWF复合物或人凝血因子VIII制剂的干热处理稳定剂
US20150080309A1 (en) * 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
US20160000884A1 (en) 2012-08-13 2016-01-07 Novo Nordisk A/S Liquid Factor VIII Formulations

Also Published As

Publication number Publication date
JP2017528440A (ja) 2017-09-28
KR102192494B1 (ko) 2020-12-18
RU2689338C2 (ru) 2019-05-27
EP3177317B1 (en) 2020-03-18
NZ729629A (en) 2021-12-24
WO2016020210A1 (en) 2016-02-11
US10238718B2 (en) 2019-03-26
BR112017002090A2 (pt) 2018-01-30
IL250343B (en) 2020-10-29
MX2017000862A (es) 2017-05-01
DK3177317T3 (en) 2020-06-15
RU2017106159A (ru) 2018-09-06
RU2017106159A3 (es) 2018-11-28
PL3177317T3 (pl) 2020-07-27
EP3177317A1 (en) 2017-06-14
SG10201900598TA (en) 2019-02-27
US20170252412A1 (en) 2017-09-07
AU2015299224B2 (en) 2019-06-20
JP6516829B2 (ja) 2019-05-22
BR112017002090B1 (pt) 2021-06-01
CN106687126A (zh) 2017-05-17
CN106687126B (zh) 2020-07-28
ES2788870T3 (es) 2020-10-23
WO2016020210A8 (en) 2016-04-28
AU2015299224A1 (en) 2017-03-23
KR20170040327A (ko) 2017-04-12
CA2956412A1 (en) 2016-02-11
SG11201700550YA (en) 2017-02-27
IL250343A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
ZA201701286B (en) Flagellin compositions and uses
ZA201901260B (en) Fragrance compositions
IL250568B (en) Anti-methanogenic preparations and their uses
ZA201702213B (en) Interleukin-15 compositions and uses thereof
EP3166574A4 (en) Cosmetic compositions
GB201420943D0 (en) Cannabinoid compositions and uses
GB201409348D0 (en) Perfume compositions
MX379126B (es) Formulación de factor viii.
EP3191549A4 (en) Organosiloxane compositions and uses thereof
GB201502002D0 (en) Uses and compositions
SI3220893T1 (sl) Sestavek na osnovi COQ10
GB201608762D0 (en) Compositions and uses thereof
ZA201707872B (en) Compositions comprising anakinra
IL249695A0 (en) Converted polymyxins and preparations containing them
MY167350A (en) Fat-and-oil composition and chocolate
GB201502026D0 (en) Uses and compositions
GB201501991D0 (en) Uses and compositions
IL251238B (en) Mineral-based compounds and their uses
GB201614897D0 (en) Compositions and uses thereof
GB201511886D0 (en) Uses and compositions
GB201602409D0 (en) Compositions and uses thereof
GB201522814D0 (en) Compositions and uses thereof
EP3183330A4 (en) Perfume compositions containing isomeric alkadienals
ZA201807664B (en) Gel compositions
ZA201805806B (en) Fragranced compositions and their use